Active specific immunotherapy potential for the treatment of large bowel cancerdoi:10.1002/1097-0142(197711)40:5+<2740::AID-CNCR2820400949>3.Active specific immunotherapy, harnessing the strength and specificity of the host immune response to destroy neoplastic cells, may offer an ideal surg...
Immunotherapy, which aims to stimulate the immune system to eradicate cancer, has recently revolutionized cancer treatment and constitutes the fourth cornerstone of cancer therapy alongside surgery, radiation, and chemotherapy [1,2]. Current cancer immunotherapy research encompasses a broad range of approac...
Immunotherapy, which aims to stimulate the immune system to eradicate cancer, has recently revolutionized cancer treatment and constitutes the fourth cornerstone of cancer therapy alongside surgery, radiation, and chemotherapy [1,2]. Current cancer immunotherapy research encompasses a broad range of approac...
The potential biological drugs and drug delivery systems against the inflammatory diseases, including cancer, atherosclerosis (AS), rheumatoid arthritis (RA), inflammatory bowel diseases (IBD) and pulmonary arterial hypertension (PAH). Download: Download high-res image (222KB) Download: Download full-...
Tumor-associated macrophages (TAMs) are a promising target for cancer immunotherapy, but delivering therapeutic agents to TAMs within the tumor microenvironment (TME) is challenging. In this study, a photosensitive, dual-targeting nanoparticle system (M.RGD@Cr-CTS-siYTHDF1 NPs) was developed. The...
Gastrointestinal (GI) cancers account for more than one-third of cancer-related mortality, and the prognosis for late-stage patients remains poor. Immunotherapy has been proven to extend the survival of patien... Authors: Chien-Jung Huang, Guan-Ting Liu, Yi-Chen Yeh, Shin-Yi Chung, Yu-Cha...
Abstract Immunotherapy for cancer has undergone a rapid expansion in classes, agents, and indications. By utilizing aspects of the body’s innate immune system, immunotherapy has improved life expectancy and quality of life for patients with several types of cancer. Adoptive cellular therapies, includi...
Genentech's first patent suggests and outlines the suitability of blocking TIGIT in the treatment of immune related diseases such as psoriasis, arthritis, inflammatory bowel disease and breast cancer, and using aberrant TIGIT expression or activity as diagnostic tool for these diseases (Clark et al....
Tumor-associated macrophages (TAMs) are a promising target for cancer immunotherapy, but delivering therapeutic agents to TAMs within the tumor microenvironment (TME) is challenging. In this study, a photosensitive, dual-targeting nanoparticle system (M.
phase 1/2 study of MDNA11 (ABILITY-1 study; NCT05086692), MDNA11 monotherapy resulted in ORR in 4/14 (29%; 1 CR, 3PR), including a patient with microsatellite instability (MSI)-high pancreatic ductal adenocarcinoma, two patients with melanoma, and one patient with small bowel cancer. Add...